Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × zimberelimab × 90 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Uterine Cervical Neoplasms 3 Carcinoma, Renal Cell 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Kidney Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Ovarian Neoplasms 1 Neoplasms 1 Metastatic Urothelial Cancer 1 Glioblastoma 1 Esophageal Neoplasms 1 Erythrocytosis, Familial, 4 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Neuroendocrine 1 Bile Duct Neoplasms 1 Advanced Solid Tumor 1

Interventions

atezolizumab 3 Etoposide 2 Cisplatin 2 zimberelimab 1 tivozanib 1 durvalumab 1 cabozantinib 1 belinostat 1 Temozolomide 1 Standard of Care 1 Positron Emission Tomography Computed Tomography 1 Nivolumab 1 Magnetic Resonance Imaging 1 Ipilimumab 1 Immunoglobulin G 1 Disulfides 1 Carboplatin 1 Capecitabine 1 CTLA-4 Antigen 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡